Platinum Drugs

Anticancer Therapeutics

Volumn , Issue , 2008, Pages 55-78

  Boulikas, Teni ^a   Pantos, Alexandros ^a   Bellis, Evagelos ^a   Christofis, Petros ^a  

^a Regulon   (Greece)

Author keywords

Conjugating DNA targeting groups to metal moiety; Epithelial malignancy cisplatin treatment; Lipoplatin formulation and dipalmitoyl phosphatidyl glycerol (DPPG); Lipoplatin primary tumour targeting; Neutrophil gelatinase associated lipocalin (NGAL) renal biomarker; New platinum based anticancer drugs; Oxaliplatin alkaline hydrolysis; Platinum drugs

Indexed keywords

EID: 84889391380     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470697047.ch5     Document Type: Chapter

References (99)

1. Ali BH, Al Moundhri MS. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research. Food Chem Toxicol 2006, 44(8), 1173-83.
2. Al-Sarraf M. Chemotherapeutic management of head and neck cancer. Cancer Metastasis Rev 1987, 6, 181-98.
3. Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol 2003, 23, 460-4.
4. Arnould S, Hennebelle I, Canal P, Bugat R, Guichard S. Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur J Cancer 2003, 39, 112-119.
5. Aronov A, Horowitz A, Gabizon A, Gibson D. Folate-Targeted PEG as a Potential Carrier for Carboplatin Analogs. Synthesis and in vitro Studies. Bioconugate Chem 2003, 14, 563-74.
6. Baas P, Belderbos JS, Senan S, et al. Concurrent chemotherapy (carboplatin, paclitaxel, etoposide) and involved-field radiotherapy in limited stage small cell lung cancer: a Dutchmulticenter phase II study. Br J Cancer 2006, 94(5), 625-30.
7. Barry CG, Day CS, Bierbach U. Duplex-promoted platination of adenine-N3 in the minor groove of DNA: challenging a longstanding bioinorganic paradigm. J Am Chem Soc 2005, 127, 1160-9.
8. Beale P, Judson I, O'Donnell A, et al. A Phase I clinical and pharmacological study of cisdiamminedichloro(2-methylpyridine) platinum II (AMD473). Br J Cancer 2003, 88, 1128-34.
9. Bonovich M, Olive M, Reed E, O'Connell B, Vinson C. Adenoviral delivery of A-FOS, an AP-1 dominant negative, selectively inhibits drug resistance in two human cancer cell lines. Cancer Gene Ther 2002, 9, 62-70.
10. Boulikas T. Gene therapy of prostate cancer: p53, suicidal genes, and other targets. Anticancer Res 1997, 17(3A), 1471-5.
11. Boulikas T, Vougiouka M. Cisplatin and platinum drugs at the molecular level. Oncol Rep 2003, 10, 1663-82.
12. Boulikas T, Vougiouka M. Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs. Oncol Rep 2004, 11, 559-95.
13. Boulikas T, Stathopoulos GP, Volakakis N, Vougiouka M. Systemic Lipoplatin infusion results in preferential tumor uptake in human studies. Anticancer Res 2005, 25, 3031-40.
14. Boulikas T, Mylonakis N, Sarikos G, et al. Lipoplatin plus gemcitabine versus cisplatin plus gemcitabine in NSCLC: Preliminary results of a phase III trial. J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I, 25, 18028.
15. Bowler BE, Ahmed KJ, Sundquist WI, Hollis LS, Whang EE, Lippard SJ. Synthesis, characterization, and DNA-binding properties of (1,2-diaminoethane)platinum(II) complexes linked to the DNA intercalator acridine orange by trimethylene and hexamethylene chains. J Am Chem Soc 1989, 111, 1299-306.
16. Brabec V, Kasparkova J, Vrana O, et al. DNA modifications by a novel bifunctional trinuclear platinum Phase I anticancer agent. Biochemistry 1999, 38, 6781-90.
17. Buller RE, Runnebaum IB, Karlan BY, et al. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther 2002a, 9, 553-66.
18. Buller RE, Shahin MS, Horowitz JA, et al. Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500. Cancer Gene Ther, 2002b, 9, 567-72.
19. Caglar K, Kinalp C, Arpaci F, et al. Cumulative prior dose of cisplatin as a cause of the nephrotoxicity of high-dose chemotherapy followed by autologous stem-cell transplantation. Nephrol Dial Transplant 2002, 17, 1931-5.
20. Carr JL, Tingle MD, McKeage M. Rapid biotransformation of satraplatin by human red blood cells in vitro. Cancer Chemother Pharmacol 2002, 50(1), 9-15.
21. Cassidy J, Misset JL. Oxaliplatin-related side effects: characteristics and management. Semin Oncol 2002, 29(Suppl 15), 11-20.
22. De Vita F, Orditura M, Matano E, et al. A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer 2005, 92(9), 1644-9.
23. Denkert C, Schmitt WD, Berger S, et al. Expression of mitogen-activated protein kinase phosphatase-1 (MKP-1) in primary human ovarian carcinoma. Int J Cancer 2002, 102, 507-13.
24. Devarajan P, Savoca M, Castaneda MP, Park MS, Esteban-Cruciani N, Kalinec G, Kalinec F. Cisplatininduced apoptosis in auditory cells: role of death receptor and mitochondrial pathways. Hear Res 2002, 174, 45-54.
25. Devarajan P, Tarabishi R, Mishra J, Ma Q, Kourvetaris A, Vougiouka M, Boulikas T. Low renal toxicity of Lipoplatin compared to cisplatin in animals. Anticancer Res 2004, 24, 2193-2200.
26. Di Felice V, Lauricella M, Giuliano M, Emanuele S, Vento R, Tesoriere G. The apoptotic effects of cisplatin and carboplatin in retinoblastoma Y79 cells. Int J Oncol 1998, 13, 225-32.
27. Di Francesco AM, Ruggiero A, Riccardi R. Cellular and molecular aspects of drugs of the future: oxaliplatin. Cell Mol Life Sci 2002, 59, 1914-27.
28. Dragovich T, Mendelson D, Kurtin S, Richardson K, Von Hoff D, Hoos A. A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer. Cancer Chemother Pharmacol 2006, 58, 759-64.
29. El Maalouf G, Rodier JM, Faivre S, Raymond E. Could we expect to improve survival in small cell lung cancer? Lung Cancer 2007, 57(Suppl 2), S30-4.
30. Farrell NP. Platinum-based Drugs in Cancer Therapy; Humana Press, Totawa, NJ, 2000.
31. Fuertes MA, Castilla J, Alonso C, Perez JM. Novel concepts in the development of platinum antitumor drugs. Curr. Med. Chem. Anticancer Agents 2002, 2(4), 539-51.
32. Fuertes MA, Castilla J, Alonso C, Perez JM. Cisplatin biochemical mechanism of action: From cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr Med Chem 2003, 10, 257-66.
33. Furin A, Guiotto A, Baccichetti F, Pasut G, Bertani R., Veronese F. Synthesis, characterization and preliminary cytotoxicity assays of poly(ethylene glycol)-malonato-Pt-DACH conjugates. Eur J Med Chem 2003, 38, 739-49.
34. Gore ME, Atkinson RJ, Thomas H, et al. A phase II trial of ZD0473 in platinum-pretreated ovarian cancer. Eur J Cancer 2002, 38, 2416-20.
35. Hall MD, Hambley TW. Platinum(IV) antitumor compounds: their bioinorganic chemistry. Coord Chem Rev 2002, 232, 49-67.
36. Highley MS; Calvert AH. In: Clinical Experience with Cisplatin and Carboplatin, edited by LR Kelland and NP Farrell. Humana Press, Totowa NJ, 2000, pp 89-113.
37. Hill JM, Speer RJ. Organo-platinum complexes as antitumor agents (review). Anticancer Res 1982, 2, 173-86.
38. Holford J, Beale PJ, Boxall FE, Sharp SY, Kelland LR. Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell lines. Eur J Cancer 2000, 36, 1984-90.
39. Holford J, Raynaud F, Murrer BA, Grimaldi K, Abrams M, Kelland LR. Chemical, biochemical and pharmacological activity of the novel sterically hindered platinum co-ordination complex, cis-[amminedichloro(2-methylpyridine)] platinum(II) (AMD473). Anticancer Drug Des 1998, 13, 1-18.
40. Holmes RJ, McKeage MJ, Murray V, Denny WA, McFadyen WD. cis-Dichloroplatinum(II) complexes tethered to 9-aminoacridine-4-carboxamides: synthesis and action in resistant cell lines in vitro. J Inorg Biochem 2001, 85, 209-17.
41. Huang R, Wu T, Xu L, Liu A, Ji Y, Hu G. Upstream binding factor up-regulated in hepatocellular carcinoma is related to the survival and cisplatin-sensitivity of cancer cells. FASEB J 2002, 16(3), 293-301.
42. Humes HD. Insights into ototoxicity. Analogies to nephrotoxicity. Ann NY Acad Sci 1999, 884, 15-18.
43. Jerremalm E, Eksborg S, Ehrsson H. Hydrolysis of oxaliplatin-evaluation of the acid dissociation constant for the oxalato monodentate complex. J Pharm Sci 2003, 92, 436-8.
44. Johnson NP, Butour JL, Villani G, Wimmer FL, Defais M, Pierson V. Metal antitumor compounds: the mechanism of action of platinum complexes. Prog Clin Biochem Med 1989, 10, 1-24.
45. Johnson SW, Ferry KV, Hamilton TC. Recent insights into platinum drug resistance in cancer. Drug Resist 1998, Update 1, 243-54.
46. Judson I, Kelland LR. New developments and approaches in the platinum arena. Drugs 2000, 59(Suppl 4), 29-36; discussion 37-38.
47. Kasparkova J, Novakova O, Vrana O, Farrell N, Brabec V. Effect of geometric isomerism in dinuclear platinum antitumor complexes on DNA interstrand cross-linking. Biochemistry 1999, 38, 10997-1005.
48. Kasparkova J, Farrell N, Brabec V. Sequence specificity, conformation, and recognition by HMG1 protein of major DNA interstrand cross-links of antitumor dinuclear platinum complexes. J Biol Chem 2000, 275(21), 15789-98.
49. Kasparkova J, Zehnulova J, Farrell N, Brabec V. DNA interstrand cross-links of the novel antitumor trinuclear platinum complex BBR3464. Conformation, recognition by high mobility group domain proteins, and nucleotide excision repair. J Biol Chem 2002, 277, 48076-86.
50. Kelland LR. An update on satraplatin: the first orally available platinum anticancer drug. Exp Opin Invest Drugs 2000, 9: 1373-82.
51. Kigawa J, Sato S, Shimada M, Takahashi M, Itamochi H, Kanamori Y, Terakawa N. p53 gene status and chemosensitivity in ovarian cancer. Hum Cell 2002, 14, 165-71.
52. Kikuno N, Urakami S, Nakamura S, et al. Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer. Eur Urol 2007, 51(5), 1252-8.
53. Kosmidis P, Mylonakis N, Nicolaides C, et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 2002, 20, 3565-7.
54. Kurata T., Tamura T., Sasaki Y., Fujii H., Negoro S., Fukuoka M., Saijo N., (2000) Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) administered once a day for five consecutive days: a phase I study. Jpn J. Clin. Oncol. 30: 377-84.
55. Lebwohl D, Canetta R. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer 1998, 34, 1522-34.
56. Lersch C, Schmelz R, Eckel F, et al. Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer. Clin Colorectal Cancer 2002, 2, 54-8.
57. Leyland-Jones B, Kelland LR, Harrap KR, Hiorns LR. Genomic imbalances associated with acquired resistance to platinum analogues. Am J Pathol 1999, 155, 77-84.
58. Lin AM, Rosenberg JE, Weinberg VK, et al. Clinical outcome of taxane-resistant (TR) hormone refractory prostate cancer (HRPC) patients (pts) treated with subsequent chemotherapy (ixabepilone (Ix) or mitoxantrone/prednisone (MP). J Clin Oncol 2006, 24(suppl), 231s (abstract 4558).
59. Lin X, Okuda T, Holzer A, Howell SB. The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. Mol Pharmacol 2002, 62(5), 1154-9.
60. Lippert B (ed.) Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug.Wiley-VCH, New York, 1999.
61. Martin F, Boulikas T. The challenge of liposomes in gene therapy. Gene Ther Mol Biol 1998, 1, 173-214.
62. Matsumara Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986, 46, 6387-92.
63. Mattern J, Stammler G, Koomagi R, Wallwiener D, Kaufmann M, Volm M. Spontaneous apoptosis in ovarian cancer: an unfavorable prognostic factor. Int J Oncol 1998, 12, 351-4.
64. McKeage MJ. New-generation platinum drugs in the treatment of cisplatin-resistant cancers. Expert Opin Investig Drugs 2005, 14(8), 1033-46.
65. Morin PJ. Drug resistance and the microenvironment: nature and nurture. Drug Resist 2003, Update 6, 169-72.
66. Nagata J, Kijima H, Hatanaka H, et al. Reversal of drug resistance using hammerhead ribozymes against multidrug resistance-associated protein and multidrug resistance 1 gene. Int J Oncol 2002, 21, 1021-6.
67. Natile G, Coluccia M. Current status of trans-platinum compounds in cancer therapy. Coord Chem Rev 2001, 216-217, 383-410.
68. Niedner H, Christen R, Lin X, Kondo A, Howell SB. Identification of genes that mediate sensitivity to cisplatin. Mol Pharmacol 2001, 60, 1153-60.
69. O'Dwyer PJ, Stevenson JP, Johnson SW. Clinical status of cisplatin, carboplatin, and other platinumbased antitumor drugs. In: Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug etited by B Lippert. Wiley-VCH, New York, 1999, pp 31-72.
70. Pein F, Michon J, Valteau-Couanet D, et al. High-dose melphalan, etoposide, and carboplatin followed by autologous stem-cell rescue in pediatric high-risk recurrent Wilms' tumor: a French Society of Pediatric Oncology study. J Clin Oncol 1998, 16(10), 3295-301.
71. Perez-Soler R, Piperdi B, Walsh GL, et al. Phase II study of a liposome-entrapped cisplatin analog (LNDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma. J Clin Oncol 2005, 23, 3495-34501.
72. Pinotti G, Martinelli B. A case of acute tubular necrosis due to oxaliplatin. Ann Oncol 2002, 13, 1951-2.
73. Qu Y, Appleton TG, Hoeschele JD, Farrell N. Cisplatin as a synthon. Synthesis and characterization of triplatinum complexes containing three cis-(Pt(amine)2 units linked in a linear fashion, Inorg Chem 1993, 32, 2591.
74. Ramalingam S, Belani CP. Taxanes for advanced non-small cell lung cancer. Exp Opin Pharmacother 2002, 3(12), 1693-709.
75. Ranson M, Thatcher N. Paclitaxel: a hope for advanced non-small cell lung cancer? Exp Opin Investig Drugs 1999, 8(6), 837-48.
76. Raymond E, Faivre S, Chaney S,Woynarowski J, Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 2002, 1, 227-35.
77. Reck M, von Pawel J, Macha HN, et al. Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: quality of life and 6-years'-follow-up results from a randomised phase III trial. Lung Cancer 2006, 53(1), 67-75.
78. Reedijk J. Improved understanding in platinum antitumor chemistry. Chem Commun 1996, 801-806.
79. Rosell R, Gatzemeier U, Betticher DC, et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 2002, 13, 1539-49.
80. Rosenberg B. Noble metal complexes in cancer chemotherapy. Adv Exp Med Biol 1977, 91, 129-50.
81. Sandercock J, Parmar MK, Torri V, Qian W. First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence. Br J Cancer 2002, 87(8), 815-24.
82. Sharp SY, Rogers PM, Kelland LR. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance. Clin Cancer Res 1995, 1, 981-9.
83. Shen DW, Goldenberg S, Pastan I, Gottesman MM. Decreased accumulation of [14C]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake. J Cell Physiol 2000, 183, 108-16.
84. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22, 7265-79.
85. Spingler B, Whittington DA, Lippard SJ. 2.4 crystal structure of an oxaliplatin 1,2-d (GpG) intrastrand cross-link in a DNA dodecamer duplex. Inorg Chem 2001, 40m 5596-602.
86. Stathopoulos GP, Boulikas T, Vougiouka M, et al. Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): Phase I study. Oncol Rep 2005, 13, 589-95.
87. Stathopoulos GP, Boulikas T, Kourvetaris A, Stathopoulos I. Liposomal oxaliplatin in the treatment of advanced cancer: a phase I study. Anticancer Res 2006, 26, 1489-94.
88. Stathopoulos GP, Michalopoulou P, Antoniou D, et al. Liposomal cisplatin and paclitaxel versus cisplatin and paclitaxel in advanced NSCLC. J Clin Oncol 2007, ASCO Annual Meeting Proceedings Part I 25, 7684.
89. Sternberg CN, Yagoda A, Scher HI, et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 1989, 64, 2448-58.
90. Sundquist WI, Bancroft DP, Chassot L, Lippard SJ. DNA promotes the reaction of cisdiamminedichloroplatinum(II) with the exocyclic amino groups of ethidium bromide. J Am Chem Soc 1988, 110, 8559-60.
91. Sundquist WI, Bancroft DP, Lippard SJ. Synthesis, characterization, and biological activity of cisdiammineplatinum(II) complexes of the DNA intercalators 9-aminoacridine and chloroquine. J Am Chem Soc 1990, 112, 1590-6.
92. Temple MD, McFadyen WD, Holmes RJ, Denny WA, Murray V. Interaction of cisplatin and DNAtargeted 9-aminoacridine platinum complexes with DNA. Biochemistry 2000, 39, 5593-9.
93. Temple MD, Recabarren P,McFadyen WD, Holmes RJ, Denny WA,Murray V. The interaction of DNAtargeted 9-aminoacridine-4-carboxamide platinum complexes with DNA in intact human cells. Biochim Biophys Acta 2002, 1574, 223-30.
94. Ueda K, Kawashima H, Ohtani S, et al. The 3p21.3 Tumor suppressor NPRL2 plays an important role in cisplatin-induced resistance in human non-small-cell lung cancer cells. Cancer Res 2006, 66, 9682-90.
95. Veal GJ, Griffin MJ, Price E, et al. A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin. Br J Cancer 2001, 84(8), 1029-35.
96. Weaver DA, Crawford EL, Warner KA, Elkhairi F, Khuder SA, Willey JC. ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. Mol Cancer 2005, 4(1), 18.
97. Wong E, Giandomenico CM. Current status of platinum-based antitumor drugs, Chem Rev 1999, 99(9), 2451-66.
98. Yamamoto M, Oshiro S, Tsugu H, Hirakawa K, Ikeda K, Soma G, Fukushima T. Treatment of recurrent malignant supratentorial astrocytomas with carboplatin and etoposide combined with recombinant mutant human tumor necrosis factor-alpha. Anticancer Res 2002, 22(4), 2447-53.
99. Zehnulova J, Kasparkova J, Farrell N, Brabec V. Conformation, recognition by high mobility group domain proteins, and nucleotide excision repair of DNA intrastrand cross-links of novel antitumor trinuclear platinum complex BBR3464. J Biol Chem 2001, 276, 22191-9.